Concepedia

Lingzhi Hong

LH

31

Publications

1.9K

Citations

20

H-Index

2007

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Nanjing Medical University

Massachusetts General Hospital

Memorial Sloan Kettering Cancer Center

Nanjing General Hospital of Nanjing Military Command

Lingzhi Hong is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, lung cancer, and pathology.

ORCID

Top concepts

Publications per year

2007–2025

31

Publications

31

Structure-based classification predicts drug response in EGFR-mutant NSCLC

Jacqulyne Robichaux, Xiuning Le, R.S.K. Vijayan et al. · Nature · 2021 · 416 citations · Full text

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

Biagio Ricciuti, Kathryn C. Arbour, Amir Vajdi et al. · Journal of Thoracic Oncology · 2021 · 346 citations · Full text

, , +10

Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC

Lingzhi Hong, Marcelo V. Negrão, Seyedeh Dibaj et al. · Journal of Thoracic Oncology · 2020 · 186 citations · Full text

Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study

Maliazurina B. Saad, Lingzhi Hong, Muhammad Aminu et al. · The Lancet Digital Health · 2023 · 99 citations · Full text

The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma

Minglei Zhuo, Yanfang Guan, Xue Yang et al. · Clinical Cancer Research · 2019 · 94 citations · Full text

Rows per page

1–5 of 31